All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-02-28T12:02:52.000Z

The safety and efficacy of spesolimab in Asian patients

Feb 28, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in psoriasis.

Bookmark this article

Spesolimab is a humanized, selective antibody, which disrupts the activation of the interleukin-36 receptor.1 The interleukin-36 pathway is involved in the pathogenesis of multiple inflammatory diseases, including generalized pustular psoriasis (GPP) in adults.

Spesolimab has been approved for use in multiple countries, including Japan, mainland China, and the European Union,1 as well as receiving approval by the U.S. Food and Drug Administration (FDA) for the treatment of GPP flares in September 2022, as summarized by the Psoriasis and Psoriatic Arthritis Hub here.1

The Psoriasis and Psoriatic Arthritis Hub has previously reported on the safety and frequency of adverse events following treatment with spesolimab in the GPP population from the randomized, double-blind, placebo-controlled phase II trial, Effisayil™ 1 (NCT03782792). Here, we summarize the safety and efficacy findings from the Effisayil™ 1 clinical trial in respect to the characteristics and outcomes of the 29 Asian participants, as reported by Morita et al.2 in The Journal of Dermatology.

Patient characteristics

The baseline characteristics among Asian patients in the spesolimab treatment and placebo groups were comparable. However, there was a greater number of female participants in the placebo group (Table 1).

Table 1. Baseline characteristics of Asian participants*

Characteristic, % (unless otherwise stated)

Spesolimab
(n = 16)

Placebo
(n = 13)

Mean age, years

42.2

43.2

Mean body weight, kg

68.1

64.0

Sex

 

 

              Female

62.5

92.3

              Male

37.5

7.7

Country of enrollment

 

 

              China

12.5

30.8

              Japan

6.3

7.7

              Malaysia

50.0

30.8

              Singapore

0.0

7.7

              Thailand

0.0

7.7

              Taiwan

18.8

15.4

              France

12.5

0.0

Present or past psoriasis†,‡

75.0

76.9

Ongoing plaque psoriasis

25.0

15.4

GPPGA total score

 

 

              3

68.8

100.0

              4

31.3

0.0

GPPGA pustulation subscore

 

 

              2

18.8

30.8

              3

43.8

46.2

              4

37.5

23.1

GPPGA, Generalized Pustular Psoriasis Physician Global Assessment.
*Data from Morita, et al.2
Data are missing for one participant in the spesolimab group.
Present or past psoriasis could encompass any type of psoriasis including plaque psoriasis, while ongoing plaque psoriasis refers exclusively to plaque psoriasis.

Efficacy

The primary endpoint in this study was a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0, defined as no visible pustules at Week 1. This primary endpoint was met in 62.5% of patients in the spesolimab group compared with 7.7% in the placebo group (risk difference, 54.8; 95% confidence interval, 17.3–79.8). A secondary endpoint of a GPPGA total score of 0 or 1 (demonstrated by clear or almost clear skin) at Week 1 was met in 50.0% and 15.4% of patients in the spesolimab and placebo group, respectively (risk difference, 34.6; 95% confidence interval, −3.1 to 64.7). The comparisons of GPPGA pustulation subscore and GPPGA total score between the spesolimab and placebo groups among Asian patients and the overall population are outlined in Figure 1.

Figure 1. Percentage of Asian patients and patients in the overall population with a GPPGA pustulation subscore of 0 or a GPPGA total score of 0 or 1 at Week 1*

GPPGA, Generalized Pustular Psoriasis Physician Global Assessment.
*Adapted from Morita, et al.2

Safety

Among Asian patients, adverse events (AEs) were reported in 68.8% of patients in the spesolimab group compared with 61.5% of patients in the placebo group at Week 1. Common AEs in the spesolimab group included urinary tract infections and peripheral edema, occurring in 12.5% of patients. In the placebo group, the more common AEs included pyrexia and dizziness, occurring in 23.1% and 15.4% of patients, respectively. No deaths were recorded in this study. Other reported AEs are displayed in Table 2.

Table 2. Adverse events occurring in Asian patients*

Event, %

Spesolimab
(n = 16)

Placebo
(n = 13)

Any AE

68.8

61.5

Common AE

 

 

              Urinary tract infection

12.5

0.0

              Headache

6.3

7.7

              Extremity pain

6.3

7.7

              Diarrhea

6.3

0.0

              Pyrexia

6.3

23.1

              Peripheral edema

12.5

7.7

              Dizziness

0.0

15.4

              Nausea

6.3

0.0

Severe AE (RCTC Grade 3 or 4)

0.0

7.7

Investigator-defined drug-related AE

31.3

38.5

Serious AE

6.3

0.0

Serious AE requiring or prolonging hospitalization

6.3

0.0

AE, adverse event; RCTC, Rheumatology Common Toxicity Criteria.
*Data from Morita, et al.2
AEs reported in ≥10% of patients in any group. AE severity was graded according to the RCTC version 2.0 safety analysis set. Pustular psoriasis was excluded as an AE from this safety analysis.
One patient was recorded to have three serious AEs by Week 1 including urinary tract infection and symptoms that were reported as drug-induced liver injury and drug reaction with eosinophilia and systemic symptoms. However, these were not considered to be associated with spesolimab.

Conclusion

Overall, the majority of characteristics and treatment outcomes among Asian patients were comparable with the overall population. Spesolimab treatment was found to improve outcomes in Asian patients compared with a placebo for GPP flares, as well as having an acceptable safety profile. The data retrieved from this analysis of the Asian participants in the Effisayil™ 1 clinical trial support the approved use of spesolimab to treat GPP in Asian patients.

  1. Boehringer Ingelheim. Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares. https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/spesolimab-meets-key-endpoint-for-gpp-flare-prevention. Published Jan 30, 2023. Accessed Feb 23, 2023.
  2. Morita A, Tsai TF, Yee EYW, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study. J Dermatol. 2023;50(2):183-194. DOI: 1111/1346-8138.16609

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox